Webcast to be Held at 8:00 am ET on
Monday, August 14, 2023
WESTPORT, Conn., Aug. 7, 2023
/PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq:
INTS), a clinical-stage biotechnology company focused on the
discovery and development of proprietary, novel immune-based
intratumoral cancer therapies designed to kill tumors and increase
immune system recognition of cancers, today announced that it
report its financial results for the second quarter ended
June 30, 2023, including a corporate
update, on Monday, August 14, 2023,
before the opening of the U.S. financial markets. A conference call
and webcast will follow at 8:00 am
ET.
To participate in the conference call, please dial
1-877-317-6789 (domestic) or 1-412-317-6789 (international). To
access a live webcast of the call, please visit:
https://ir.intensitytherapeutics.com/news-events/events-presentations.
An archived replay of the webcast will be available for one year
on the Intensity Therapeutics website at:
https://ir.intensitytherapeutics.com/news-events/events-presentations.
About Intensity Therapeutics
Intensity Therapeutics,
Inc. is a clinical-stage biotechnology company pioneering a new
immune-based approach to treat solid tumor cancers. Intensity
leverages its DfuseRx℠ technology platform to create proprietary
drug formulations that following direct injection rapidly disperse
throughout a tumor and diffuse therapeutic agents into cancer
cells. Intensity's product candidates have the potential to induce
an adaptive immune response that not only attacks the injected
tumor, but also non-injected tumors. The Company's lead product
candidate, INT230-6, is in development for the treatment of
patients with solid tumors, such as sarcoma and breast cancer.
Intensity has a clinical collaboration agreement with Merck Sharpe
& Dohme (Merck) to evaluate INT230-6 with pembrolizumab. In
addition, the Company has a clinical collaboration agreement with
Bristol-Myers Squibb to evaluate the combination INT230-6 with
Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. Intensity
has also executed agreements with the Ottawa Hospital Research
Institute (OHRI) and the Ontario Institute of Cancer Research
(OICR) to study INT230-6 in a randomized controlled neoadjuvant
phase 2 study in women with early stage breast cancer (the
INVINCIBLE study) (NCT04781725). Additionally, the Company executed
a Cooperative Research and Development Agreement (CRADA) with the
National Cancer Institute's (NCI) Vaccine Branch. For more
information, please visit www.intensitytherapeutics.com and follow
the Company on Twitter @IntensityInc.
Forward-Looking Statements
Certain statements in this
press release may constitute "forward-looking statements" within
the meaning of the United States Private Securities Litigation
Reform Act of 1995, as amended to date. These statements include,
but are not limited to, statements relating to the expected trading
commencement, closing dates and use of proceeds. We have based
these forward-looking statements on our current expectations and
projections about future events, nevertheless, actual results or
events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, include: the risk that the initial public
offering of common stock may not close, as well as other risks
described in the section entitled "Risk Factors" in the prospectus,
which can be obtained on the SEC website at www.sec.gov. Readers
are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contact Information
Investor Relations Contact:
Rx Communications
Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
US Media Contact:
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original
content:https://www.prnewswire.com/news-releases/intensity-therapeutics-to-announce-financial-results-for-the-second-quarter-ended-june-30-2023-and-provide-corporate-update-301893391.html
SOURCE Intensity Therapeutics, Inc.